2015 American Transplant Congress
Graft Outcome Disparity in a Single Renal Transplant Center Based on Recipient Geographic Origin
University of Toledo Medical Center, Toledo, OH.
PURPOSE: The disparity in access to organs for kidney transplantation has led to inter-state “transplant tourism.” Our objective was to determine if recipients traveling over…2015 American Transplant Congress
CPRA Values Are Substantially Increased for Some Candidates Subsequent to Inclusion of Unacceptable C-locus (UA-C) Antigens While Listing Practices Remain Unchanged
1UNOS, Richmond; 2Emory University Hospital, Atlanta; 3Stanford University, Palo Alto.
Background: CPRA is the % of deceased donors expected to have one or more UAs with a given candidate. Prior to 12/5/13, candidates with UA-C…2015 American Transplant Congress
TGR5 Regulates Innate Immune Responses in Mouse Liver Ischemia-Reperfusion Injury Through NRF2/HO-1 Signaling Pathway
The G-Protein-Coupled Bile Acid Receptor (TGR5), also called Gpbar1 or GPBA, is a G-protein coupled plasma membrane receptor for Bile acids (BAs) which is expressed…2015 American Transplant Congress
Clusterin-Regulated Transcriptome in the Kidney During Ischemia-Reperfusion
BACKGROUND: Ischemia-reperfusion injury (IRI) has a significate impact on both short and long-term transplant outcomes, and is a major cause of delayed graft function in…2015 American Transplant Congress
24 Month Post Transplantation Follow Up of the Certitem Trial
Background: CERTITEM has evaluated the effect of everolimus/calcineurin inhibitors free (CNI free) on fibrosis progression and results have been reported at 12 months (M12). Data…2015 American Transplant Congress
Increasing Tacrolimus Exposure to Minumize Chronic Rejection: How Can We Do It? What Are the Risks?
Background: Recent studies suggest that increased tacrolimus (TAC) exposure may help prevent production of donor specific HLA antibodies (DSAs) that mediate chronic rejection of renal…2015 American Transplant Congress
Outcomes of Kidney Transplant Recipients Minimally Immunosuppressed: A Cohort Study Analysis
Background: Renal transplantation is the treatment of choice for endstage renal disease. Nevertheless, it involves immunosuppressive treatments with Serious Adverse Events (SAE) such as infections…2015 American Transplant Congress
Tacrolimus for the Treatment of Refractory Biopsy-Proven Acute Cellular Rejection in Patients on Belatacept-Based, CNI- and Steroid-Free Immunosuppression Regimens
1Univ of Cincinnati, Cincinnati; 2The Christ Hospital, Cincinnati.
Background: Tacrolimus (TAC) is effective as rescue treatment (tx) in renal transplant patients (pts) on cyclosporine-based immunosuppression (IS) who have recurrent or resistant acute rejection…2015 American Transplant Congress
Unrecognized Synchronous Hepatocellcular Carcinoma Lesions in Explanted Liver Transplant Specimens
Introduction: Liver resection for early-stage hepatocellular carcinoma (HCC) is limited by high surgical risk in cirrhotics and high rates of intrahepatic recurrence. We postulated that…2015 American Transplant Congress
Suboptimal Vaccination Coverage After Liver Transplantation: Opportunity for Improvement
Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Elimination of vaccine-preventable disease after solid organ transplantation (SOT) has the potential to improve outcomes. We evaluated immunization rates and the impact of directed recommendations…
- « Previous Page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- …
- 170
- Next Page »